News

Amgen and Wyeth have issued a statement in response to the FDA announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers. TNF blocker

Sagent Pharmaceuticals has launched ondansetron in 5% dextrose injection in premix bags. Its an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by

The US and European patent authorities have granted seven additional patents to Gen-Probe. It extend the company’s intellectual property estate related to automated instrument systems for nucleic acid

Boehringer Ingelheim is going to initiate phase III clinical study of BIBW 2992 (Tovok), as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor

Micronics has been awarded a Small Business Technology Transfer grant totaling approximately $440,000, to develop a rapid method for nucleic acid detection of known and emerging respiratory infections.

Law firm, Glancy Binkow & Goldberg has filed a lawsuit in the US District Court of Massachusetts, seeking a class action status on behalf of a class consisting

MannKind reported a net loss for the second quarter of 2009 of $55.6 million, or $0.54 per share, compared to a net loss of $79.8 million, or $0.79

SuperGen has reported preliminary results from phase Ib data of MP-470, tyrosine kinase and RAD51 suppressor. The results demonstrated an overall clinical benefit rate of 54%, when the

Arkema has posted sales figures of E1.16 billion, as compared to E1.5 billion in the second quarter of 2008, a decline of 22.7%. EBITDA stood at E70 million,